natgillin/translations-raw huggingface dataset:
With regard to the medicine’s side effects, the most frequent were mild to moderate in severity.
Resnost najpogostejših neželenih učinkov zdravila je bila blaga do zmerna.
With regard to the safety profile, it was considered acceptable provided the recommendations in place are observed.
Z vidika profila tveganja je menil, da je sprejemljiv, če se upoštevajo podana priporočila.
With regards to the safety profile, the most common adverse events observed during treatment with Plegridy are considered to be manageable and generally consistent with those seen with non-pegylated interferon products.
Glede na varnostni profil so bili najpogostejši neželeni učinki, opaženi med zdravljenjem z zdravilom Plegridy, obvladljivi in na splošno skladni z neželenimi učinki, ki so jih opazili pri nepegiliranih interferonih.
with renal and/or hepatic
okvaro ledvic in/ali jeter, ker
With repeated confirmation of liver transaminases above 5 times the ULN, treatment with Gilenya should be interrupted and only re-commenced once liver transaminase values have normalised.
Če ponovna preiskava potrdi koncentracije jetrnih aminotransferaz nad 5- kratno vrednostjo ZMN, je treba zdravljenje z zdravilom Gilenya prekiniti in ga ponovno uvesti šele po tem, ko se vrednosti jetrnih aminotransferaz normalizirajo.
With repeated daily administration, sunitinib accumulates 3- to 4-fold and its primary active metabolite accumulates 7- to 10-fold.
S ponavljajočo se dnevno uporabo se sunitinib nakopiči 3- do 4-kratno, njegov primarni aktivni presnovek pa 7- do 10-kratno.
With respect to NSCLC, the CHMP noted that Keytruda helps prolong survival and slows the worsening of the disease.
Kar zadeva nedrobnocelični pljučni rak je odbor CHMP ugotovil, da zdravilo Keytruda pomaga podaljšati čas preživetja in upočasni poslabševanje bolezni.
With respect to patients with giant cell tumour of bone the possibility of complete surgical removal of the tumour after treatment and the reduction in extent of the surgery needed in some patients were considered clinically important.
Pri bolnikih z gigantocelularnim kostnim tumorjem so kot klinično pomembno ocenili možnost popolne kirurške odstranitve tumorja po zdravljenju in zmanjšanje obsega kirurškega posega, ki so ga nekateri potrebovali.
With respect to reproduction no effects on pregnancy, embryo-foetal development, parturition or postnatal development were observed after intravenous administration of vernakalant at exposure levels (AUC) similar or below the human exposure levels (AUC) achieved after a single intravenous dose of vernakalant.
Kar zadeva sposobnost razmnoževanja, ni bilo ugotovljenih učinkov na nosečnost, embriofetalni razvoj, porod ali postnatalni razvoj po intravenski uporabi vernakalanta ob izpostavljenosti (AUC), podobni ali manjši od izpostavljenosti (AUC), dosežene pri človeku po enem samem intravenskem odmerku vernakalanta.
With respect to testosterone levels (an established surrogate marker of fertility), during clinical trials 68 % of dogs administered one implant, returned to fertility within 2 years of implantation.
Glede na plazemsko koncentracijo testosterona (ki je uveljavljen nadomestni označevalec plodnosti) se je med kliničnimi preskusi 68 % psov, ki so jim dali po en implantat, v 2 letih po implantaciji vrnila plodnost.
With respect to testosterone levels (i.e. an established surrogate marker of fertility), during clinical trials 68 % of dogs administered one implant, returned to fertility within 2 years of implantation.
Glede na plazemsko koncentracijo testosterona (ki je uveljavljen nadomestni označevalec plodnosti) se je med kliničnimi preskusi 68 % psov, ki so jim dali po en implantat, v 2 letih po implantaciji vrnila plodnost.
With respect to the primary efficacy endpoint, the proportion (%) of patients achieving HIV RNA < 50 copies/ml at Week 48 was 241/280 (86.1 %) in the group receiving ISENTRESS and 230/281 (81.9 %) in the group receiving efavirenz.
Pri upoštevanju učinkovitosti kot primarnega opazovanega dogodka je bil delež (%) bolnikov, ki so dosegli HIV RNA < 50 kopij/ml v 48. tednu, v skupini, ki je prejemala zdravilo ISENTRESS 241/280 (86,1 %), v skupini, ki je prejemala efavirenz pa 230/281 (81,9 %).
with rifabutin or
flukonazolom ali
with rifampicin as
obliko itrakonazola,
with ritonavir-boosted atazanavir
očasno z atazanavirjem, ojačanim
with rosuvastatin.
očasno z rosuvastatinom.
With rotigotine, the mean reductions in “off” time were 2.7 and 2.1 hours, respectively whereas in the placebo-treated arm a reduction of 0.9 hours was observed.
Pri skupini, ki je prejemala placebo, je bilo zmanjšanje 0,9 ure.
With routine laboratory monitoring it was seen that approximately 24% of patients receiving RoActemra in clinical trials experienced sustained elevations in total cholesterol ≥ 6.2 mmol/ l, with 15% experiencing a sustained increase in LDL to ≥ 4.1 mmol/ l.
Rutinsko laboratorijsko spremljanje je pokazalo, da se je pri približno 24 % bolnikov, ki so v kliničnih preskušanjih dobivali zdravilo RoActemra, pojavilo dolgotrajno zvišanje celotnega holesterola na ≥ 6,2 mmol/l, pri 15 % pa dolgotrajno zvišanje LDL na ≥ 4,1 mmol/l.
with screw cap (PP)
pipeta z navojno
with screw cap (PP)
pipeta z navojno zaporko
with screw cap (PP)
Polipropilenska
with screw cap (PP)
zaporko
With seizure disorders
z motnjami napadov,
with separate needle 10 pre-filled syringes
10 napolnjenih brizg
with separate needles 1 single dose vial
1 enoodmerna viala
with separate needles 50 pre-filled syringes
50 napolnjenih brizg
with severe or unstable or uncontrolled cardiovascular disease; with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sjögren’s syndrome.
hudo ali nestabilno ali nekontrolirano kardiovaskularno boleznijo; z depresijo, cerebralno ali koronarno insuficienco, Raynaudovim fenomenom, ortostatsko hipotenzijo, obliterantnim trombangiitisom, sklerodermo ali Sjögrenovim sindromom.
with severe renal and hepatic impairment
hudo okvaro ledvic ali jeter,
with severe renal impairment with severe hepatic impairment
hudimi okvarami ledvic s hudimi okvarami jeter
With sexual stimulation you may achieve an erection anywhere from 25 minutes up to four to five hours after taking Vivanza.
Če ste spolno vzburjeni, lahko erekcijo dosežete že v 25 minutah oz. najkasneje v štirih do petih urah po zaužitju tablete.
With significant renal impairment
z znatnim poslabšanjem delovanja ledvic,
with sirolimus requires
zahteva bistveno
with skeletal malignancies or bone metastases.
skeletnimi malignostmi ali kostnimi metastazami
With St John’s Wort (Hypericum Perforatum), due to its strong CYP3A4 inducing effect, caution should be exercised when taken concurrently with pitolisant.
Previdnost je potrebna tudi pri sočasni uporabi pitolizanta s šentjanževko (Hypericum perforatum), ki močno inducira CYP3A4.
with stavudine.
očasno s stavudinom.
with sulpho- nylurea
rčno popuščanje4
with sulpho- nylurea
sulfonil- sečnino
with systemic fluconazole
klaritromicinom ali
with tacrolimus requires
zahteva bistveno
With Tenofovir 300 mg once daily
S tenofovirjem v odmerku 300 mg enkrat na dan
with tenofovir disoproxil fumarate
očasno z dizoproksiltenofovirat
With Tenofovir disoproxil fumarate 300 mg once daily
Z dizoproksiltenofovirat fumaratom v odmerku 300 mg enkrat na dan
with tenofovir disoproxil fumarate or with emtricitabine.
fumaratom ali emtricitabinom.
with tenofovir, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
posebej pri bolnikih s sistemsko ali ledvično boleznijo, ali pri bolnikih,
With the 200/100 mg daily dose regimen at an infusion rate of 1.1 mg/min, the steady state Cmax and trough concentrations (Cmin) could reach approximately 7 and 3 mg/l, respectively, with an average steady state AUC of approximately 110 mgh/l.
Z odmerno shemo 200/100 mg na dan in hitrostjo infundiranja 1,1 mg/min lahko v stanju dinamičnega ravnovesja Cmax doseže 7 mg/l, najnižja koncentracija (Cmin) pa 3 mg/l; povprečna AUC v stanju dinamičnega ravnovesja je približno 110 mgh/l.
With the bevel of the needle facing upwards, insert the catheter laterally 1.5 to 2 cm into the subcutaneous layer at a 30 to 45 degree angle to the skin surface in one continuous flowing movement.
Kateter z enim neprekinjenim gibom lateralno vstavite 1,5 do 2 cm v subkutano plast pod kotom 30 do 45 stopinj na kožno površino, pri čemer naj bo poševna konica igle obrnjena navzgor.
With the blood clot broken down, blood can flow more easily into the heart muscle, allowing the heart to keep working and helping to save the patient’s life.
Po razgraditvi strdka kri lažje steče v srčno mišico, kar srcu omogoča nadaljnje delovanje, bolniku pa možnost preživetja.
With the bottle on a flat surface, insert the PIBA into the bottle neck while keeping the PIBA’s flat surface facing up and pressing on it (Figure 2).
Plastenko položite na ravno površino, medtem ko držite nastavek za peroralno brizgo z gladko povržino navzgor, pritisnite nanjo in potisnite nastavek za peroralno brizgo v vrat plastenke (Slika 2).
With the bottle upright, fit the tip of the syringe into the bottle adapter.
Plastenko držite v pokončnem položaju in namestite konico brizge na nastavek.
With the catheter in place, aseptically remove the implant from the vial.
Ko je kateter vstavljen, aseptično odstranite implantat iz viale.
With the clear cartridge pointing up, gently swirl the pen for one minute.
Z prozornim vložkom obrnjenim navzgor previdno vrtite peresnik eno minuto.
With the current knowledge, a possible risk for the development of lymphomas, leukemia, and other malignancies in patients treated with a TNF-antagonist cannot be excluded.
S sedanjim znanjem možnega tveganja za razvoj limfomov, levkemije in drugih malignomov pri bolnikih, zdravljenih z antagonistom TNF, ni mogoče izključiti.
With the Enbrel vial upright on a flat surface, such as a table, insert the syringe needle straight down through the centre ring of the grey stopper of the vial (see Diagram 2).
Ko je viala z zdravilom Enbrel postavljena pokončno na ravni površini, na primer mizi, zabodite iglo brizge naravnost navzdol skozi osrednji obroč sivega zamaška viale (glejte sliko 2).
With the exception of headache and migraine, no systemic adverse drug reactions were identified with the use of OZURDEX.
Z izjemo glavobola in migrene niso bili zabeleženi nobeni sistemski neželeni učinki uporabe zdravila OZURDEX.
With the exception of infections and related symptoms that were more frequently reported in patients <2 years of age, the safety profile was similar in all paediatric age groups.
Razen okužb in povezanih simptomov, o katerih so pogosteje poročali pri bolnikih, starih do <2 leti, je bil varnostni profil podoben v vseh pediatričnih starostnih skupinah.
With the exception of ritonavir for which co-administration with sildenafil is not advised (see section 4.4) a starting dose of 25 mg should be considered in patients receiving concomitant treatment with CYP3A4 inhibitors (see section 4.5).
Pri bolnikih, ki sočasno dobivajo zaviralce CYP3A4, je priporočeni začetni odmerek 25 mg (glejte poglavje 4.5) razen pri ritonavirju, katerega sočasna uporaba s sildenafilom ni priporočljiva (glejte poglavje 4.4).
With the free hand, gently grasp the cleaned area of skin and hold firmly.
S prosto roko obzirno primite očiščeni predel kože in ga trdno držite.
With the needle point up, gently tap the clear cartridge 2-3 times to bring large air bubbles to the top.
Rahlo 2-krat ali 3-krat potrkajte po prozornem vložku, da se bodo veliki zračni mehurčki dvignili na vrh.
With the needle pointed at the vial, align the “0.5 ml” mark on the syringe with the edge of the dose preparation guide.
Iglo, usmerjeno proti viali, poravnajte tako, da bo znak “0,5 ml” na brizgi poravnan z robom vodila za pripravo odmerka.
With the needle still in the vial, hold the dose preparation guide with the vial upside down at eye level.
Ko je igla še vedno v viali, dvignite podstavek tako, da bo viala obrnjena na glavo, približno v višini oči.
With the needle still in the vial, hold the vial upside down at eye level.
Ko je igla še vedno v viali, dvignite vialo tako, da bo obrnjena na glavo, približno v višini oči.
With the needle still in the vial, turn the vial upside down at eye level.
Medtem ko je igla še vedno v viali, v višini oči obrnite vialo na glavo.
With the needle still inserted in the vial, check the syringe for air bubbles.
Ko je igla še vedno v viali, preverite, ali so v brizgi zračni mehurčki.
With the needle still inserted in the vial, check the syringe for air bubbles.
Medtem ko je igla še vedno v viali, preverite, ali so v brizgi zračni mehurčki.
With the needle still pointing upwards, press slowly the dose setting knob as far as it will go.
Z iglo še vedno usmerjeno navzgor počasi do konca pritisnite gumb za nastavitev odmerka.
With the other hand grasp the solvent-side and unscrew the set carefully counterclockwise into two pieces to avoid excessive build-up of foam when dissolving the product.
Z drugo roko primite na strani vehikla in z odvijanjem v nasprotni smeri urinega kazalca previdno razstavite komplet na dva dela, da se izognete pretiranemu nastajanju pene pri raztapljanju zdravila.
With the other hand, hold syringe at 45-degree angle to skin, with the grooved side up.
Z drugo roko držite brizgo pod kotom 45 stopinj na kožo, z užlebljenim delom obrnjenim navzgor.
With the other hand, hold syringe at 45-degree angle to skin.
Z drugo roko držite brizgo pod kotom 45 stopinj na kožo.
With the other hand, hold syringe at a 45-degree angle to skin.
Z drugo roko primaknite brizgo h koži pod kotom 45 stopinj.
With the other hand, hold the base of your penis with the fingers (see illustration below).
S prsti druge roke držite koren penisa (glejte spodnjo risbo).
With the other hand, hold the plunger and unscrew the syringe from the vial.
Z drugo roko primite bat in odvijte brizgo z viale.
With the other hand, hold the syringe at a 45-degree angle to the skin.
Z drugo roko primaknite brizgo h koži pod kotom 45 stopinj.
With the other hand, insert the needle at an angle of 90 degrees into the skin’s surface, as shown in the picture (f).
Z drugo roko vbodite iglo v kožo pod kotom 90 stopinj, kakor je prikazano na sliki (f).
With the other hand, push straight down firmly on the adaptor package until you feel the adaptor spike penetrate the vial stopper and FEEL AND HEAR THE ADAPTOR RIM LOCK INTO PLACE (see Diagram 3).
Z drugo roko MOČNO pritisnite embalažo z adapterjem NARAVNOST NAVZDOL, dokler ne začutite, da je konica adapterja predrla gumijasti zamašek viale in OBČUTITE TER SLIŠITE, da je ADAPTER NAMEŠČEN (glejte sliko 3).
with the PSURs.
Rezultate vmesne
With the reconstitution spike and syringe still attached to the vial, swirl the vial gently to dissolve the Rapilysin 10 U powder.
S pripomočkom za pripravo in injekcijsko brizgo, še vedno pritrjenima na vialo, nežno zanihajte vialo, da raztopite prašek zdravila Rapilysin 10 enot.
With the ReFacto AF pre-filled syringe on top, slowly depress the plunger rod until the contents empty into the 10 cc or larger luer lock syringe.
V položaju, ko se napolnjena injekcijska brizga zdravila ReFacto AF nahaja zgoraj, počasi potiskajte bat noter, dokler vsebina ne preide v 10 cm3 ali večjo brizgo z Luer nastavkom.
With the renal route being a minor route of elimination for eluxadoline, no dose adjustment based on renal function may be necessary (see sections 4.4 and 5.2).
Ker je izločanje skozi ledvice manj pomembna pot izločanja eluksadolina, prilagajanje odmerka na podlagi delovanja ledvic morda ne bo potrebno (glejte poglavji 4.4 in 5.2).
With the syringe still attached to the vial and vial adaptor, hold the vial upside down at eye level.
Ko je brizga še vedno pritrjena na vialo in adapter, primite vialo obrnjeno na glavo, približno v višini oči.
With the syringe still attached, gently move the vial in circles a few times, to dissolve the powder (see Diagram 9).
Medtem ko je brizga še vedno v viali, nekajkrat nežno krožno zavrtite vialo, da se prašek raztopi (glejte sliko 9).
With the tip of the needle placed within the plaque, initiate injection, maintaining steady pressure to slowly inject the drug into the plaque.
S konico igle v plaku začnite z injiciranjem in ohranjajte stalni pritisk za počasno injiciranje zdravila v plak.
With the use of factor IX products obtained from CHO cells very rarely development of antibodies to hamster protein has been observed.
Z uporabo zdravil faktorja IX, pridobljenega iz celic CHO (celice jajčnika kitajskega hrčka – Chinese hamster ovary), so zelo redko opazili pojav protiteles proti proteinom hrčka.
With the use of the higher-dosed COCs (50 g ethinylestradiol) the risk of endometrial and ovarian cancer is reduced.
Pri uporabi visoko odmernih COC (50 g etinilestradiola) je tveganje za rak endometrija ali jajčnikov zmanjšano.
With the use of the higher-dosed COCs (50 g ethinylestradiol) the risk of endometrial and ovarian cancer is reduced.
Pri uporabi visoko odmernih KPK (50 g etinilestradiola) je tveganje za rak endometrija ali jajčnikov zmanjšano.
With the vial held upside down, unscrew the syringe from the vial adaptor by turning it anti-clockwise (see Diagram 12).
Vialo še vedno držite zasukano na glavo in odvijte brizgo iz adapterja tako, da jo zavrtite v nasprotno smer urnega kazalca (glejte sliko 12).
With the vial placed upright on a flat surface, insert the needle and transfer the water for injections into the vial containing the lyophilised powder using standard aseptic techniques, directing the water for injections directly on to the powder.
Postavite vialo pokonci na vodoravno površino, zapičite iglo in vbrizgajte vodo za injekcije v vialo z liofiliziranim praškom, pri tem uporabljajte standardne aseptične tehnike, vodo za injekcije pa usmerite naravnost v prašek.
With the vial standing on a flat surface, insert the needle straight through the rubber stopper into the vial.
Viala naj stoji na ravni podlagi in vanjo naravnost skozi gumijasto zaporko vstavite iglo.
with these anticonvulsants
navedenih antiaritmikov.
With these updated data, therapy discontinuation due to adverse events was observed in 17.1% of patients treated with ruxolitinib.
Ob upoštevanju tako dopolnjenih podatkov je do prekinitve zdravljenja zaradi neželenih učinkov prišlo pri 17,1 % bolnikov, ki so prejemali ruksolitinib.
With third degree AV block occurring at any time.
če kadarkoli pride do atrioventrikularnega bloka tretje stopnje,
With this, people find themselves becoming increasingly impaired, whether or not they have relapses.
Bolniki s to obliko postajajo vedno bolj prizadeti, ne glede na to, ali imajo relapse ali ne.
with tipranavir is not recommended (see section 4.2).
tipranavirjem ni priporočljiva (glejte poglavje 4.2).
With Toujeo SoloStar pre-filled pen, a dose of 1-80 units per injection, in steps of 1 unit, can be injected.
Z napolnjenim injekcijskim peresnikom Toujeo SoloStar je mogoče injicirati odmerek od 1 do 80 enot na injekcijo v koraku po 1 enoto.
With Tresiba 100 units/mL a dose of 1-80 units per injection, in steps of 1 unit, can be administered.
Pri zdravilu Tresiba 100 enot/ml se lahko izbere odmerek 1-80 enot na injekcijo, v korakih po 1 enoto.
With Tresiba 200 units/mL a dose of 2-160 units per injection, in steps of 2 units, can be administered.
Pri zdravilu Tresiba 200 enot/ml se lahko izbere odmerek 2-160 enot na injekcijo, v korakih po 2 enoti.
With Tresiba, hypersensitivity (manifested with swelling of tongue and lips, diarrhoea, nausea, tiredness and itching) and urticaria were reported rarely.
Pri zdravilu Tresiba so o preobčutljivosti (ki se kaže v obliki otekanja jezika in ustnic, driske, navzeje, utrujenosti in srbenja) in urtikariji poročali redko.
With triple pack “4” you can inject the full dose 1.0 ml.
S trojnim pakiranjem »4« lahko injicirate celotni odmerek 1 ml.
with uncontrolled or significant cardiac disease including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia. taking anti-arrhythmic medicinal products or other substances that lead to QT prolongation.
z neurejeno ali klinično pomembno boleznijo srca, vključno z nedavnim miokardnim infarktom, s kongestivnim srčnim popuščanjem, z nestabilno angino pektoris ali s klinično pomembno bradikardijo, ki jemljejo antiaritmična zdravila ali druga sredstva, ki povzročajo podaljšanje intervala QT.
with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia. taking antiarrhythmic medicinal products or other substances that are known to lead to QT prolongation (see section 4.5). with hypokalaemia and/or hypomagnesaemia.
z neurejeno ali s pomembno boleznijo srca, kar vključuje nedavni miokardni infarkt, kongestivno srčno popuščanje, nestabilno angino pektoris in klinično pomembno bradikardijo; ki jemljejo antiaritmike ali druge učinkovine, za katere je znano, da povzročajo podaljšanje intervala QT (glejte poglavje 4.5); s hipokaliemijo in/ali hipomagneziemijo.
with unexplained elevations of bone-specific alkaline phosphatase
Pagetovo boleznijo kosti) z zvišanimi ravnmi za kosti značilne alkalne fosfataze brez ugotovljenega vzroka
with unexplained vaginal bleeding.
z ginekološkimi krvavitvami nepojasnjenega vzroka;
With up to 3 years of exposure, no patients receiving both adefovir dipivoxil and lamivudine developed resistance to adefovir dipivoxil.
Pri izpostavljenosti do 3 let ni noben bolnik, ki je prejemal dipivoksiladefovirat in lamivudin, razvil rezistence proti dipivoksiladefoviratu.
With up to one year of treatment with Pegasys in combination with ribavirin, some children and adolescents did not grow or gain weight as much as expected.
V času zdravljenja z zdravilom Pegasys v kombinaciji z ribavirinom, ki je trajalo do enega leta, nekateri otroci in mladostniki niso zrastli oziroma pridobili toliko telesne mase kot pričakovano.
with Victrelis.
očasni uporabi zdravila
With your free hand, hold the syringe near its base to stabilise it.
S prosto roko držite iglo blizu baze, da jo stabilizirate.
With your free hand, pick up the needle package with the yellow syringe connector facing down.
S prosto roko primite pakiranje igle, in sicer tako, da rumeni konektor za brizgo gleda navzdol.
With your hands over the container, hold the capsule with the cap facing up (see illustration b).
Kapsulo držite nad posodo s hrano tako, da je pokrovček kapsule obrnjen navzgor (glejte sliko b).
With your non-dominant hand, secure the patient’s hand to be treated while simultaneously applying tension to the cord.
S svojo nedominantno roko primite bolnikovo roko, ki jo boste zdravili, hkrati pa napnite vozlič.
With your other hand hold the syringe as you would a pencil.
Z eno roko oblikujte kožno gubo, in sicer tako, da kožo dvignete in stisnete med dva prsta, z drugo pa držite brizgo kot svinčnik.
With your other hand, gently bend your penis in the opposite direction of the curve (see illustration below).
Z drugo roko nežno upognite penis v smeri nasproti ukrivljenosti (glejte spodnjo sliko).
With your other hand, gently pinch the cleaned skin.
Z drugo roko očiščeno kožo stisnite v gubo.
With your thumb press the injection button slowly and steadily to inject your medicine.
S palcem počasi in enakomerno pritisnite gumb za injiciranje, da boste injicirali zdravilo.
With zidovudine or stavudine, it is not certain if Ribavirin BioPartners will change the way these medicines work.
Ni znano, ali lahko zdravilo Ribavirin BioPartners spremeni delovanje teh zdravil.
With zidovudine or stavudine, it is not certain if ribavirin will change the way these medicines work.
Pri jemanju skupaj z zidovudinom ali stavudinom ni gotovo, če ribavirin spremeni delovanje teh zdravil.
with zidovudine.
očasno z zidovudinom.
Withdraw
pakiranja
Withdraw 0.2 ml of reconstituted vaccine into a 1 ml or 2 ml syringe, remove the needle and administer the whole contents of the syringe into one of the cat’s nostrils.
Odvzemite 0,2 ml rekonstituiranega cepiva z 1- ali 2-mililitrsko brizgo, snemite iglo in mački vse cepivo v brizgi vbrizgajte v eno nosnico.